Helsinki-based Valo Therapeutics has secured EUR 2.23 million from the European Innovation Council to progress their innovative PeptiCHIP technology.

Valo Therapeutics, a spinout company from the University of Helsinki, is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious disease. The immunotherapy company has now secured funding of over EUR 2 million from the European Innovation Council (EIC) to progress their innovative PeptiCHIP technology. PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalised immunotherapies.“I’m delighted that the EIC has chosen to support us as we develop PeptiCHIP alongside our clinical development program. Identification of relevant antigens is one of the key challenges in developing effective immunotherapies for cancer”, says Paul Higham, CEO of Valo Therapeutics.Health Capital Helsinki